Cover Image
市場調查報告書

冠狀動脈繞道手術:醫療設備的開發平台評估

Coronary Artery Bypass Graft Surgery - Medical Devices Pipeline Assessment, 2018

出版商 GlobalData 商品編碼 357845
出版日期 內容資訊 英文 138 Pages
訂單完成後即時交付
價格
Back to Top
冠狀動脈繞道手術:醫療設備的開發平台評估 Coronary Artery Bypass Graft Surgery - Medical Devices Pipeline Assessment, 2018
出版日期: 2018年06月14日 內容資訊: 英文 138 Pages
簡介

本報告提供冠狀動脈繞道手術相關之開發中產品調查,提供您各開發階段趨勢和產品的主要開發企業,現在進行中的臨床實驗,產業的近幾年趨勢等資訊。

第1章 目錄

第2章 簡介

  • 冠狀動脈繞道手術概要

第3章 開發中的產品

  • 冠狀動脈繞道手術 - 開發中產品:各開發階段
  • 冠狀動脈繞道手術 - 開發中產品:各市場區隔
  • 冠狀動脈繞道手術 - 開發中產品:各地區 (國家)
  • 冠狀動脈繞道手術 - 開發中產品:各法規途徑
  • 冠狀動脈繞道手術 - 開發中產品:各核准時期 (估計)
  • 冠狀動脈繞道手術 - 持續中臨床實驗

第4章 冠狀動脈繞道手術 - 正在開發的開發中產品:各企業

  • 冠狀動脈繞道手術企業 - 開發中產品:各開發階段
  • 冠狀動脈繞道手術 - 開發中產品:各開發階段

第5章 冠狀動脈繞道手術 開發企業與產品概要

  • AdvanSource Biomaterials Corporation
  • Axcelon Biopolymers Corp.
  • CardioPolymers, Inc.
  • CellProthera
  • Coromedic Ltd.
  • Cytograft Tissue Engineering, Inc.
  • Elana bv
  • Endogene Ltd
  • Graft-Loc Inc.
  • H. Lee Moffitt Cancer Center & Research Institute, Inc.
  • iiTech BV
  • Magenta Medical Inc
  • Miracor Medical Systems GmbH
  • Neograft Technologies, Inc.
  • NuVascular Technologies Inc
  • Prekubator TTO
  • Revivicor, Inc.
  • SeamVad Ltd.
  • St. Jude Medical, Inc.
  • Tengion, Inc.
  • The University of Utah
  • Tissue Regeneration Technologies, LLC
  • University College London
  • University of Arizona
  • University of California, Los Angeles

第6章 冠狀動脈繞道手術 - 近幾年趨勢

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0587EPD

GlobalData's Medical Devices sector report, "Coronary Artery Bypass Graft Surgery - Medical Devices Pipeline Assessment, 2018" provides an overview of Coronary Artery Bypass Graft Surgery currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Coronary Artery Bypass Graft Surgery pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Coronary Artery Bypass Graft Surgery under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Coronary Artery Bypass Graft Surgery and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Coronary Artery Bypass Graft Surgery under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 7

2 Introduction 8

  • 2.1 Coronary Artery Bypass Graft Surgery Overview 8

3 Products under Development 9

  • 3.1 Coronary Artery Bypass Graft Surgery - Pipeline Products by Stage of Development 9
  • 3.2 Coronary Artery Bypass Graft Surgery - Pipeline Products by Segment 10
  • 3.3 Coronary Artery Bypass Graft Surgery - Pipeline Products by Territory 11
  • 3.4 Coronary Artery Bypass Graft Surgery - Pipeline Products by Regulatory Path 12
  • 3.5 Coronary Artery Bypass Graft Surgery - Pipeline Products by Estimated Approval Date 13

4 Coronary Artery Bypass Graft Surgery - Pipeline Products under Development by Companies 14

  • 4.1 Coronary Artery Bypass Graft Surgery Companies - Pipeline Products by Stage of Development 14
  • 4.2 Coronary Artery Bypass Graft Surgery - Pipeline Products by Stage of Development 16

5 Coronary Artery Bypass Graft Surgery Companies and Product Overview 17

  • 5.1 AdvanSource Biomaterials Corporation Company Overview 17
  • 5.2 Axcelon Biopolymers Corp. Company Overview 18
  • 5.3 CardioPolymers Inc Company Overview 19
  • 5.4 Cardious Inc Company Overview 20
  • 5.5 Centre Hospitalier Universitaire de Nice Company Overview 21
  • 5.6 Coromedic Ltd. Company Overview 22
  • 5.7 Cytograft Tissue Engineering Inc (Inactive) Company Overview 24
  • 5.8 Elana bv Company Overview 25
  • 5.9 Endogene Ltd Company Overview 27
  • 5.10 Graft-Loc Inc. Company Overview 28
  • 5.11 H. Lee Moffitt Cancer Center & Research Institute Inc Company Overview 29
  • 5.12 Hancock Jaffe Laboratories Inc Company Overview 30
  • 5.13 Humacyte Inc Company Overview 31
  • 5.14 iiTech BV Company Overview 32
  • 5.15 Magenta Medical Inc Company Overview 34
  • 5.16 McGill University Company Overview 35
  • 5.17 Miracor Medical Systems GmbH Company Overview 36
  • 5.18 Neograft Technologies Inc Company Overview 37
  • 5.19 PetVivo Holdings Inc Company Overview 38
  • 5.20 Prekubator TTO Company Overview 39
  • 5.21 RegenMedTX LLC Company Overview 40
  • 5.22 Rox Medical Inc Company Overview 41
  • 5.23 SeamVad Ltd. Company Overview 42
  • 5.24 Thoratec Corp Company Overview 43
  • 5.25 Tissue Regeneration Technologies LLC Company Overview 44
  • 5.26 University College London Company Overview 45
  • 5.27 University of Arizona Company Overview 46
  • 5.28 University of California Los Angeles Company Overview 47
  • 5.29 University of Michigan Company Overview 48
  • 5.30 University of Utah Company Overview 49

6 Coronary Artery Bypass Graft Surgery- Recent Developments 50

  • 6.1 May 28, 2018: Beactica Signs Three-Year Extension Agreement With Sanofi 50
  • 6.2 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results 50
  • 6.3 May 14, 2018: Autologous Stem Cell Therapy May Hold Key to Regeneration 52
  • 6.4 May 09, 2018: U.S. Stem Cell Reports First Quarter Results 53
  • 6.5 May 09, 2018: Sanofi lays off 95 workers in Framingham 54
  • 6.6 May 08, 2018: Sanofi Announces Appointment of Mr. Charles Billard as Chief Financial Officer and Key Managerial Personnel 54
  • 6.7 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy 54
  • 6.8 May 02, 2018: Cardiovascular Systems Reports Fiscal 2018 Third-Quarter Financial Results 55
  • 6.9 Apr 27, 2018: Sanofi: First-quarter 2018 Business EPS up 1.4% at CER 56
  • 6.10 Apr 26, 2018: AtriCure Reports First Quarter 2018 Financial Results 64
  • 6.11 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018 65
  • 6.12 Apr 25, 2018: LeMaitre Q1 2018 Sales $26.0mm (+8%), EPS $0.19 (+17%) 67
  • 6.13 Apr 25, 2018: KARL STORZ OR1 Operating Rooms - Now Assisting the Surgical Team at Spital Thun, Switzerland 68
  • 6.14 Apr 24, 2018: Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1 68
  • 6.15 Apr 16, 2018: USRM Reports 2017 Financial Results 69
  • 6.16 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics 70
  • 6.17 Mar 28, 2018: Sanofi: Pre - quarterly Results Communication 71
  • 6.18 Mar 27, 2018: Moffitt Is Only Cancer Center In Florida Named 2018 LGBTQ Healthcare Equality Leader 72
  • 6.19 Mar 06, 2018: Sanofi's Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director 73
  • 6.20 Feb 26, 2018: AtriCure Announces Fourth Quarter and Full Year 2017 Financial Results 74
  • 6.21 Feb 21, 2018: LeMaitre Reports Net Income Of $4.3mm In Q4 2017 75
  • 6.22 Feb 20, 2018: AtriCure Names Scott Drake Board Chairman 75
  • 6.23 Feb 07, 2018: Cardiovascular Systems Reports Fiscal 2018 Second-Quarter Financial Results 76
  • 6.24 Feb 07, 2018: Sanofi Delivers 2017 Business EPS in line with Guidance 78
  • 6.25 Feb 06, 2018: USRM Seeing Explosive Increase in Demand for Stem Cell Therapy 79
  • 6.26 Feb 02, 2018: Cardiovascular Systems Appoints Jeff Points as Chief Financial Officer 80
  • 6.27 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017 81
  • 6.28 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region 83
  • 6.29 Jan 24, 2018: Cardiovascular Systems Appoints Rhonda Robb as New Chief Operating Officer 83
  • 6.30 Jan 19, 2018: Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee 84
  • 6.31 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017 84
  • 6.32 Jan 08, 2018: AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2017 85
  • 6.33 Dec 19, 2017: Bob White Named Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group; Chris Lee to Assume Leadership of Medtronic's Asia Pacific Region 85
  • 6.34 Nov 21, 2017: Medtronic Reports Second Quarter Financial Results 86
  • 6.35 Nov 09, 2017: Dextera Surgical Reports Fiscal 2018 First Quarter Financial Results 89
  • 6.36 Nov 08, 2017: Medtronic Announces Preliminary Second Quarter Revenue 90
  • 6.37 Nov 06, 2017: Ethicon Celebrates 130 Years of Transforming Surgery to Advance Patient Outcomes 91
  • 6.38 Nov 02, 2017: Medtronic Releases Fiscal Year 2017 Integrated Performance Report 92
  • 6.39 Nov 02, 2017: Sanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed 93
  • 6.40 Nov 01, 2017: AtriCure Reports Third Quarter 2017 Financial Results 101
  • 6.41 Oct 26, 2017: ROX Medical Announces Sustained Improvements in Patients with Uncontrolled Hypertension Treated with the ROX Coupler 101
  • 6.42 Oct 26, 2017: LeMaitre Q3 2017 Sales $24.8mm (+7%), Record EPS $0.25 (+49%) 102
  • 6.43 Oct 26, 2017: Boston Scientific Announces Results For Third Quarter 2017 103
  • 6.44 Oct 25, 2017: Cardiovascular Systems Reports Fiscal 2018 First-Quarter Financial Results 104
  • 6.45 Oct 09, 2017: Dextera Surgical's C-Port Distal Anastomosis System to Be Featured at the 31st Annual European Association for Cardio-Thoracic Surgery 106
  • 6.46 Oct 06, 2017: Medtronic Provides Update on Impact from Hurricane Maria 106
  • 6.47 Oct 05, 2017: Dextera Surgical Provides Corporate Update 108
  • 6.48 Oct 04, 2017: Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary 108
  • 6.49 Oct 03, 2017: ROX Medical CONTROL HTN-2 Clinical Trial; First Procedure Performed 108
  • 6.50 Sep 18, 2017: Cardiovascular Systems Announces Anticipated Revenue Impact from Hurricanes Harvey and Irma 109
  • 6.51 Aug 28, 2017: FDA warns US Stem Cell Clinic of significant deviations 109
  • 6.52 Aug 28, 2017: U.S. Stem Cell Clinic Acknowledges Warning Letter By The FDA and Responds 110
  • 6.53 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 111
  • 6.54 Aug 17, 2017: Dextera Surgical's Automated Cardiac Anastomotic Device C-Port Distal Anastomosis System to Be Featured at 2017 International Coronary Congress 113
  • 6.55 Aug 17, 2017: Dextera Surgical's Automated Cardiac Anastomotic Device PAS-Port System to Be Featured at 2017 International Coronary Congress 114

6.56 Aug 09, 2017: U.S. Stem Cell Reports Most Successful Financial Performance in the Company's History 116

  • 6.57 Aug 08, 2017: Dextera Surgical Reports Fiscal 2017 Fourth Quarter Financial Results 116
  • 6.58 Aug 02, 2017: Cardiovascular Systems Reports Fiscal 2017 Fourth-Quarter Financial Results 117
  • 6.59 Aug 02, 2017: SAMHSA announces $6 million in grants to support the International President's Emergency Plan for AIDS Relief Addiction Technology Transfer Centers 119
  • 6.60 Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 120
  • 6.61 Jul 27, 2017: LeMaitre Q2 2017 Record Sales $25.8 mm (+15%), Record EPS $0.23 (+69%) 127
  • 6.62 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 128
  • 6.63 Jul 27, 2017: AtriCure Reports Second Quarter 2017 Financial Results 129
  • 6.64 Jul 18, 2017: AtriCure Announces Hiring of Chief Technology Officer 130
  • 6.65 Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 131
  • 6.66 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 132

7 Appendix 135

  • 7.1 Methodology 135
  • 7.2 About GlobalData 138
  • 7.3 Contact Us 138
  • 7.4 Disclaimer 138

List of Tables

1.1 List of Tables

  • Table 1: Coronary Artery Bypass Graft Surgery - Pipeline Products by Stage of Development 9
  • Table 2: Coronary Artery Bypass Graft Surgery - Pipeline Products by Segment 10
  • Table 3: Coronary Artery Bypass Graft Surgery - Pipeline Products by Territory 11
  • Table 4: Coronary Artery Bypass Graft Surgery - Pipeline Products by Regulatory Path 12
  • Table 5: Coronary Artery Bypass Graft Surgery - Pipeline Products by Estimated Approval Date 13
  • Table 6: Coronary Artery Bypass Graft Surgery Companies - Pipeline Products by Stage of Development 14
  • Table 7: Coronary Artery Bypass Graft Surgery - Pipeline Products by Stage of Development 16
  • Table 8: AdvanSource Biomaterials Corporation Pipeline Products & Ongoing Clinical Trials Overview 17
  • Table 9: CardioPass - Product Status 17
  • Table 10: CardioPass - Product Description 17
  • Table 11: Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 18
  • Table 12: BNC - PVA Based Vascular Graft - Product Status 18
  • Table 13: BNC - PVA Based Vascular Graft - Product Description 18
  • Table 14: CardioPolymers Inc Pipeline Products & Ongoing Clinical Trials Overview 19
  • Table 15: Plexisyl-AF - Product Status 19
  • Table 16: Plexisyl-AF - Product Description 19
  • Table 17: Cardious Inc Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 18: AvA Aortic Valve Bypass Graft System - Product Status 20
  • Table 19: AvA Aortic Valve Bypass Graft System - Product Description 20
  • Table 20: Centre Hospitalier Universitaire de Nice Pipeline Products & Ongoing Clinical Trials Overview 21
  • Table 21: Shark Anastomosis Connector - Product Status 21
  • Table 22: Shark Anastomosis Connector - Product Description 21
  • Table 23: Coromedic Ltd. Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 24: Distal Anastomosis Device - Product Status 22
  • Table 25: Distal Anastomosis Device - Product Description 22
  • Table 26: Proximal Anastomosis Device - Product Status 23
  • Table 27: Proximal Anastomosis Device - Product Description 23
  • Table 28: Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 24
  • Table 29: LifeLine TEBV - CABG - Product Status 24
  • Table 30: LifeLine TEBV - CABG - Product Description 24
  • Table 31: Elana bv Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 32: Artificial Vessel - Product Status 25
  • Table 33: Artificial Vessel - Product Description 25
  • Table 34: ELANA CLIP 3.0 - Product Status 26
  • Table 35: ELANA CLIP 3.0 - Product Description 26
  • Table 36: Endogene Ltd Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 37: Linear Vascular Anastomosis System - Product Status 27
  • Table 38: Linear Vascular Anastomosis System - Product Description 27
  • Table 39: Graft-Loc Inc. Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 40: Graft-Loc Device - Product Status 28
  • Table 41: Graft-Loc Device - Product Description 28
  • Table 42: H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 43: Vascular Stent - Product Status 29
  • Table 44: Vascular Stent - Product Description 29
  • Table 45: Hancock Jaffe Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 46: CoreoGraft - Product Status 30
  • Table 47: CoreoGraft - Product Description 30
  • Table 48: Humacyte Inc Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 49: HUMACYL Graft - CABG - Product Status 31
  • Table 50: HUMACYL Graft - CABG - Product Description 31
  • Table 51: iiTech BV Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 52: S² Distal Anastomotic System - Product Status 32
  • Table 53: S² Distal Anastomotic System - Product Description 32
  • Table 54: S² Proximal Anastomotic System - Product Status 33
  • Table 55: S² Proximal Anastomotic System - Product Description 33
  • Table 56: Magenta Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 57: Magenta Device - Congestive Heart Failure - Product Status 34
  • Table 58: Magenta Device - Congestive Heart Failure - Product Description 34
  • Table 59: McGill University Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 60: Transcatheter Aorta Pulmonary Shunt - Product Status 35
  • Table 61: Transcatheter Aorta Pulmonary Shunt - Product Description 35
  • Table 62: Miracor Medical Systems GmbH Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 63: PiCSOAMI Impulse Console - CABG - Product Status 36
  • Table 64: PiCSOAMI Impulse Console - CABG - Product Description 36
  • Table 65: Neograft Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 66: Angioshield - Product Status 37
  • Table 67: Angioshield - Product Description 37
  • Table 68: PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 69: Coronary Artery Bypass Graft - Product Status 38
  • Table 70: Coronary Artery Bypass Graft - Product Description 38
  • Table 71: Prekubator TTO Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 72: Snapcon - Product Status 39
  • Table 73: Snapcon - Product Description 39
  • Table 74: RegenMedTX LLC Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 75: Neo-Vessel Replacement - Coronary Artery Bypass - Product Status 40
  • Table 76: Neo-Vessel Replacement - Coronary Artery Bypass - Product Description 40
  • Table 77: Rox Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 78: ROX Anastomotic Coupler System - Product Status 41
  • Table 79: ROX Anastomotic Coupler System - Product Description 41
  • Table 80: SeamVad Ltd. Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 81: MySide - Product Status 42
  • Table 82: MySide - Product Description 42
  • Table 83: Thoratec Corp Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 84: Automated Anastomosis Device - Product Status 43
  • Table 85: Automated Anastomosis Device - Product Description 43
  • Table 86: Tissue Regeneration Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 87: Cardiogold - Product Status 44
  • Table 88: Cardiogold - Product Description 44
  • Table 89: University College London Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 90: Small Diameter Conduit - Product Status 45
  • Table 91: Small Diameter Conduit - Product Description 45
  • Table 92: University of Arizona Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 93: Vascular Anastomosis Device - Product Status 46
  • Table 94: Vascular Anastomosis Device - Product Description 46
  • Table 95: University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 96: Sutureless Anastomosis Device - Product Status 47
  • Table 97: Sutureless Anastomosis Device - Product Description 47
  • Table 98: University of Michigan Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 99: Arterial Everter - Product Status 48
  • Table 100: Arterial Everter - Product Description 48
  • Table 101: University of Utah Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 102: Automated Arterial Anastomotic Device - Product Status 49
  • Table 103: Automated Arterial Anastomotic Device - Product Description 49
  • Table 104: Glossary 137

List of Figures

1.2 List of Figures

  • Figure 1: Coronary Artery Bypass Graft Surgery - Pipeline Products by Stage of Development 9
  • Figure 2: Coronary Artery Bypass Graft Surgery - Pipeline Products by Segment 10
  • Figure 3: Coronary Artery Bypass Graft Surgery - Pipeline Products by Territory 11
  • Figure 4: Coronary Artery Bypass Graft Surgery - Pipeline Products by Regulatory Path 12
  • Figure 5: Coronary Artery Bypass Graft Surgery - Pipeline Products by Estimated Approval Date 13
Back to Top